News about Market

Novo Nordisk Brings World's First Once-Weekly Basal Insulin Awiqli to India

Novo Nordisk India has launched Awiqli, the world's first once-weekly basal insulin, offering adults with diabetes a more convenient treatment option with fewer injections.

Market | 10/07/2026 | By News Bureau |  206

Evonik Invests USD 100 Million to Expand US Drug Manufacturing

Evonik is investing USD 100 million to upgrade its US drug substance Contract Development and Manufacturing (CDMO) facility, expanding manufacturing capacity to meet growing demand for US-based pharmaceutical outsourcing.

Market | 10/07/2026 | By News Bureau

UK Life Sciences Attracts Investment to Create Jobs and Faster Patient Treatments

The UK life sciences sector has attracted over £3 billion in public-private investment in the past year, accelerating innovation, creating jobs, and improving patient access to new treatments.

Market | 10/07/2026 | By News Bureau

Orchid Pharma Partners with Pharmasyntez to Commercialise Exblifep in Russia

Orchid Pharma has signed an exclusive licensing and supply agreement with Pharmasyntez JSC for Exblifep in Russia. The partnership is expected to strengthen access to advanced antimicrobial therapies while addressing the growing challenge of antibiotic resistance.

Market | 09/07/2026 | By News Bureau

Dr. Reddy's Delays Semaglutide Supplies Following API-Related Quality Issue

Dr. Reddy's Laboratories announces a temporary delay in commercial supplies of semaglutide after identifying an API-related quality issue affecting certain batches. The company is investigating the root cause and has confirmed that patient safety and existing global regulatory filings remain unaffected.

Market | 09/07/2026 | By News Bureau

Vivani Medical and Novo Nordisk Sign Agreement to Evaluate Long-Acting Semaglutide Implant for Weight Management

Vivani Medical has entered into an agreement with Novo Nordisk to evaluate NPM-139, its ultra long-acting semaglutide implant for chronic weight management. The implant aims to offer a convenient once- or twice-yearly treatment option, with Phase 1 clinical trials expected to commence in mid-2026.

Market | 09/07/2026 | By News Bureau

Sino Biopharma and AstraZeneca Sign Licensing Deal for TQC3721

Sino Biopharmaceutical has signed an exclusive licensing agreement with AstraZeneca to develop, manufacture, and commercialise TQC3721, a novel PDE3/4 inhibitor for respiratory diseases.

Market | 09/07/2026 | By News Bureau |  109

Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili

Biocon has published pivotal clinical data supporting the effectiveness of Yesafili, its Food and Drug Administration (FDA)-approved interchangeable aflibercept biosimilar, demonstrating comparable safety, efficacy, and immunogenicity.

Market | 09/07/2026 | By News Bureau |  133

Astex and Genentech Partner to Develop Precision Small Molecule Therapies for Breast Cancer

Astex Pharmaceuticals has entered into an exclusive global research and licensing agreement with Genentech to advance small molecule therapies for breast cancer. The deal includes a USD 25 million upfront payment to Astex and potential milestone payments exceeding USD 490 million, alongside tiered royalties on future product sales.

Market | 07/07/2026 | By News Bureau

Sanyou Bio, Baiyunshan Xihe Partner to Advance AI-Driven Radiopharmaceutical Development

Sanyou Biopharmaceuticals and Guangzhou Baiyunshan Xihe Health Pharmaceutical have entered a strategic partnership to co-develop innovative radiopharmaceuticals and radiodiagnostic products.

Market | 07/07/2026 | By News Bureau